Literature DB >> 7909800

I domain of beta 2 integrin lymphocyte function-associated antigen-1 contains a binding site for ligand intercellular adhesion molecule-1.

A M Randi1, N Hogg.   

Abstract

Lymphocyte function-associated antigen-1 (LFA-1) is a beta 2 integrin that participates in a broad range of leukocyte functions through binding to its ligand intercellular adhesion molecule-1 (ICAM-1). The location of the ICAM-1 binding site on LFA-1 is not known. A approximately 200-amino acid "inserted" or "I" domain, which is part of the beta 2 integrin alpha subunit, is homologous to the "A" domains found in the adhesive protein von Willebrand factor and in a number of other proteins. In von Willebrand factor, the A domains are involved in ligand binding, but their function in the other proteins is still unclear. In this report, we show that the LFA-1 I domain contains a binding site for ICAM-1, which can be expressed as an isolated functional unit. The I domain contains the epitopes for 18 out of 20 anti-LFA-1 monoclonal antibodies, many of which interfere with the interaction between LFA-1 and ICAM-1. The I domain binds directly to purified recombinant ICAM-1 and also inhibits LFA-1-dependent T cell adhesion to ICAM-1. This report establishes the I domain as an ICAM-1 binding region in LFA-1 and the first ligand binding site to be identified in a beta 2 integrin.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7909800

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  24 in total

Review 1.  Alpha E beta 7.

Authors:  P J Kilshaw
Journal:  Mol Pathol       Date:  1999-08

2.  Locking in alternate conformations of the integrin alphaLbeta2 I domain with disulfide bonds reveals functional relationships among integrin domains.

Authors:  C Lu; M Shimaoka; Q Zang; J Takagi; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-02-27       Impact factor: 11.205

Review 3.  Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere.

Authors:  Charles A Whittaker; Richard O Hynes
Journal:  Mol Biol Cell       Date:  2002-10       Impact factor: 4.138

4.  Reversibly locking a protein fold in an active conformation with a disulfide bond: integrin alphaL I domains with high affinity and antagonist activity in vivo.

Authors:  M Shimaoka; C Lu; R T Palframan; U H von Andrian; A McCormack; J Takagi; T A Springer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-05-15       Impact factor: 11.205

Review 5.  Factors controlling permeability of the blood-brain barrier.

Authors:  Mohammed M A Almutairi; Chen Gong; Yuexian G Xu; Yanzhong Chang; Honglian Shi
Journal:  Cell Mol Life Sci       Date:  2015-09-24       Impact factor: 9.261

6.  The second domain of intercellular adhesion molecule-1 (ICAM-1) maintains the structural integrity of the leucocyte function-associated antigen-1 (LFA-1) ligand-binding site in the first domain.

Authors:  P Stanley; A McDowall; P A Bates; J Brashaw; N Hogg
Journal:  Biochem J       Date:  2000-10-01       Impact factor: 3.857

7.  Defining extracellular integrin alpha-chain sites that affect cell adhesion and adhesion strengthening without altering soluble ligand binding.

Authors:  C Pujades; R Alon; R L Yauch; A Masumoto; L C Burkly; C Chen; T A Springer; R R Lobb; M E Hemler
Journal:  Mol Biol Cell       Date:  1997-12       Impact factor: 4.138

8.  Crystal structure of the I-domain from the CD11a/CD18 (LFA-1, alpha L beta 2) integrin.

Authors:  A Qu; D J Leahy
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

Review 9.  Redox-relevant aspects of the extracellular matrix and its cellular contacts via integrins.

Authors:  Johannes A Eble; Flávia Figueiredo de Rezende
Journal:  Antioxid Redox Signal       Date:  2014-01-08       Impact factor: 8.401

10.  Intercellular adhesion molecule-1 dimerization and its consequences for adhesion mediated by lymphocyte function associated-1.

Authors:  J Miller; R Knorr; M Ferrone; R Houdei; C P Carron; M L Dustin
Journal:  J Exp Med       Date:  1995-11-01       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.